Simon T Barry (Simon Barry)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 59

Top Topics

Advanced Non Small Cell Lung Cancer

Estrogen Receptor

Dna Damage Response

Top Venues

Nature communications

British journal of cancer

Nature medicine

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Alissandra L Hillis, Timothy D Martin, Haley E Manchester, Jenny Högström, Na Zhang, Emmalyn Lecky, Nina Kozlova, Jonah Lee, Nicole S Persky, David E Root, Myles A Brown, Karen Cichowski, Stephen J Elledge, Taru Muranen, David A Fruman, Simon T Barry, John Gerard Clohessy, Ralitsa R Madsen, Alex Toker
Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer. Cancer research (2024)
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa Lynne Johnson, Sophie Cousin, Dong Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John Victor Heymach
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature medicine 30 (3) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Emily C Erickson, Inchul You, Grace E Perry, Aurélien J F Dugourd, Katherine Aleisha Donovan, Claire Crafter, Jeffrey W Johannes, Stuart Charles Williamson, Jennifer I Moss, Susana Ros, Robert E Ziegler, Simon T Barry, Eric S Fischer, Nathanael S Gray, Ralitsa R Madsen, Alex Toker
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Science signaling 17 (825) (2024)
Azadeh C Bashi, Elizabeth A Coker, Krishna C Bulusu, Patricia Jaaks, Claire Crafter, Howard Lightfoot, Marta Milo, Katrina McCarten, David F Jenkins, Dieudonne van der Meer, James T Lynch, Syd Barthorpe, Courtney L Andersen, Simon T Barry, Alexandra Beck, Justin Cidado, Jacob A Gordon, Caitlin Hall, James A Hall, Iman Mali, Tatiana Mironenko, Kevin Mongeon, James Morris, Laura Richardson, Paul D Smith, Omid Tavana, Charlotte Tolley, Frances Thomas, Brandon S Willis, Wanjuan Yang, Lenka Oplustil O'Connor, Ultan McDermott, Susan E Critchlow, Lisa Drew, Stephen E Fawell, Jerome T Mettetal, Mathew J Garnett
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations. Cancer discovery 14 (5) (2024)
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa Lynne Johnson, Sophie Cousin, Dong Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John Victor Heymach
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature medicine 30 (3) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63 (8) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Andreas Dannhorn, Emine Kazanc, Lucy Flint, Fei Guo, Alfie Carter, Andrew R Hall, Stewart A Jones, George Poulogiannis, Simon T Barry, Owen James Sansom, Josephine Bunch, Zoltan Takats, Richard J A Goodwin
Morphological and molecular preservation through universal preparation of fresh-frozen tissue samples for multimodal imaging workflows. Nature protocols (2024)
Jan-Niklas May, Jennifer I Moss, Florian Mueller, Susanne K Golombek, Ilaria Biancacci, Larissa Rizzo, Asmaa Said Elshafei, Felix Gremse, Robert Pola, Michal Pechar, Tomas Etrych, Svea Becker, Christian Trautwein, Roman David Bülow, Peter Boor, Ruth Knuechel, Saskia von Stillfried, Gert Storm, Sanyogitta Puri, Simon T Barry, Volkmar Schulz, Fabian Kießling, Marianne B Ashford, Twan Lammers
Histopathological biomarkers for predicting the tumour accumulation of nanomedicines. Nature biomedical engineering (2024)
Emily C Erickson, Inchul You, Grace E Perry, Aurélien J F Dugourd, Katherine Aleisha Donovan, Claire Crafter, Jeffrey W Johannes, Stuart Charles Williamson, Jennifer I Moss, Susana Ros, Robert E Ziegler, Simon T Barry, Eric S Fischer, Nathanael S Gray, Ralitsa R Madsen, Alex Toker
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Science signaling 17 (825) (2024)
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa Lynne Johnson, Sophie Cousin, Dong Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John Victor Heymach
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature medicine (2024)
Brandon S Willis, Kevin Mongeon, Hannah Dry, India L Neveras, Nadezda Bryan, Meghana Pandya, Justine Roderick-Richardson, Wendan Xu, Li Yang, Alan Rosen, Corinne Reimer, Liliana Tuskova, Pavel Klener, Jerome T Mettetal, Georg Lenz, Simon T Barry
Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma. Leukemia (2024)
Emily C Erickson, Inchul You, Grace E Perry, Aurélien J F Dugourd, Katherine Aleisha Donovan, Claire Crafter, Jeffrey W Johannes, Stuart Charles Williamson, Jennifer I Moss, Susana Ros, Robert E Ziegler, Simon T Barry, Eric S Fischer, Nathanael S Gray, Ralitsa R Madsen, Alex Toker
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Science signaling 17 (825) (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63 (8) (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63 (8) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer (2024)
Richard J A Goodwin, Stefan J Platz, Jorge Sergio Reis-Filho, Simon T Barry
Accelerating Drug Development Using Spatial Multi-omics. Cancer discovery 14 (4) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer (2024)
Nikita Sushentsev, Gregory Hamm, Lucy Flint, Daniel Birtles, Aleksandr Zakirov, Jack Richings, Stephanie Ling, Jennifer Y Tan, Mary A McLean, Vinay Ayyappan, Ines Horvat Menih, Cara Brodie, Jodi L Miller, Ian Geoffrey Mills, Vincent J Gnanapragasam, Anne Y Warren, Simon T Barry, Richard J A Goodwin, Tristan Barrett, Ferdia A Gallagher
Metabolic imaging across scales reveals distinct prostate cancer phenotypes. Nature communications 15 (1) (2024)
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa Lynne Johnson, Sophie Cousin, Dong Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John Victor Heymach
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature medicine 30 (3) (2024)
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa Lynne Johnson, Sophie Cousin, Dong Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John Victor Heymach
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature medicine 30 (3) (2024)
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa Lynne Johnson, Sophie Cousin, Dong Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John Victor Heymach
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature medicine 30 (3) (2024)
Emily C Erickson, Inchul You, Grace E Perry, Aurélien J F Dugourd, Katherine Aleisha Donovan, Claire Crafter, Jeffrey W Johannes, Stuart Charles Williamson, Jennifer I Moss, Susana Ros, Robert E Ziegler, Simon T Barry, Eric S Fischer, Nathanael S Gray, Ralitsa R Madsen, Alex Toker
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Science signaling 17 (825) (2024)
Azadeh C Bashi, Elizabeth A Coker, Krishna C Bulusu, Patricia Jaaks, Claire Crafter, Howard Lightfoot, Marta Milo, Katrina McCarten, David F Jenkins, Dieudonne van der Meer, James T Lynch, Syd Barthorpe, Courtney L Andersen, Simon T Barry, Alexandra Beck, Justin Cidado, Jacob A Gordon, Caitlin Hall, James A Hall, Iman Mali, Tatiana Mironenko, Kevin Mongeon, James Morris, Laura Richardson, Paul D Smith, Omid Tavana, Charlotte Tolley, Frances Thomas, Brandon S Willis, Wanjuan Yang, Lenka Oplustil O'Connor, Ultan McDermott, Susan E Critchlow, Lisa Drew, Stephen E Fawell, Jerome T Mettetal, Mathew J Garnett
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations. Cancer discovery 14 (5) (2024)
Azadeh C Bashi, Elizabeth A Coker, Krishna C Bulusu, Patricia Jaaks, Claire Crafter, Howard Lightfoot, Marta Milo, Katrina McCarten, David F Jenkins, Dieudonne van der Meer, James T Lynch, Syd Barthorpe, Courtney L Andersen, Simon T Barry, Alexandra Beck, Justin Cidado, Jacob A Gordon, Caitlin Hall, James A Hall, Iman Mali, Tatiana Mironenko, Kevin Mongeon, James Morris, Laura Richardson, Paul D Smith, Omid Tavana, Charlotte Tolley, Frances Thomas, Brandon S Willis, Wanjuan Yang, Lenka Oplustil O'Connor, Ultan McDermott, Susan E Critchlow, Lisa Drew, Stephen E Fawell, Jerome T Mettetal, Mathew J Garnett
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations. Cancer discovery 14 (5) (2024)
Nikita Sushentsev, Gregory Hamm, Lucy Flint, Daniel Birtles, Aleksandr Zakirov, Jack Richings, Stephanie Ling, Jennifer Y Tan, Mary A McLean, Vinay Ayyappan, Ines Horvat Menih, Cara Brodie, Jodi L Miller, Ian Geoffrey Mills, Vincent J Gnanapragasam, Anne Y Warren, Simon T Barry, Richard J A Goodwin, Tristan Barrett, Ferdia A Gallagher
Metabolic imaging across scales reveals distinct prostate cancer phenotypes. Nature communications 15 (1) (2024)
Azadeh C Bashi, Elizabeth A Coker, Krishna C Bulusu, Patricia Jaaks, Claire Crafter, Howard Lightfoot, Marta Milo, Katrina McCarten, David F Jenkins, Dieudonne van der Meer, James T Lynch, Syd Barthorpe, Courtney L Andersen, Simon T Barry, Alexandra Beck, Justin Cidado, Jacob A Gordon, Caitlin Hall, James A Hall, Iman Mali, Tatiana Mironenko, Kevin Mongeon, James Morris, Laura Richardson, Paul D Smith, Omid Tavana, Charlotte Tolley, Frances Thomas, Brandon S Willis, Wanjuan Yang, Lenka Oplustil O'Connor, Ultan McDermott, Susan E Critchlow, Lisa Drew, Stephen E Fawell, Jerome T Mettetal, Mathew J Garnett
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations. Cancer discovery 14 (5) (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics (2024)
Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina M Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa S Carnevalli, Fernando J Calero-Nieto, Gemma N Jones, Andrew J Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J Carl Barrett, Arsene-Bienvenu Loembé, Serge Y Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A Nance, Carlos Alberto Gomez Roca, Elaine B Cadogan, Susan E Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I Gabrilovich, Simon T Barry
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nature communications 15 (1) (2024)
Ursula Grazini, Aleksandra A Markovets, Lucy Ireland, Daniel O'Neill, Benjamin Phillips, Man Xu, Matthias Pfeifer, Tereza Vaclova, Matthew J Martin, Ludovic Bigot, Luc Friboulet, Ryan J Hartmaier, Maria Emanuela Cuomo, Simon T Barry, Paul D Smith, Nicolas Floc'h
Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina M Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa S Carnevalli, Fernando J Calero-Nieto, Gemma N Jones, Andrew J Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J Carl Barrett, Arsene-Bienvenu Loembé, Serge Y Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A Nance, Carlos Alberto Gomez Roca, Elaine B Cadogan, Susan E Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I Gabrilovich, Simon T Barry
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nature communications 15 (1) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63 (8) (2024)
Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina M Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa S Carnevalli, Fernando J Calero-Nieto, Gemma N Jones, Andrew J Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J Carl Barrett, Arsene-Bienvenu Loembé, Serge Y Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A Nance, Carlos Alberto Gomez Roca, Elaine B Cadogan, Susan E Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I Gabrilovich, Simon T Barry
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nature communications 15 (1) (2024)
Nikita Sushentsev, Gregory Hamm, Lucy Flint, Daniel Birtles, Aleksandr Zakirov, Jack Richings, Stephanie Ling, Jennifer Y Tan, Mary A McLean, Vinay Ayyappan, Ines Horvat Menih, Cara Brodie, Jodi L Miller, Ian Geoffrey Mills, Vincent J Gnanapragasam, Anne Y Warren, Simon T Barry, Richard J A Goodwin, Tristan Barrett, Ferdia A Gallagher
Metabolic imaging across scales reveals distinct prostate cancer phenotypes. Nature communications 15 (1) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Lorna Hopcroft, Eleanor M Wigmore, Stuart Charles Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer 9 (1) (2023)
Peter A Kreuzaler, Paolo Inglese, Avinash D Ghanate, Ersa Gjelaj, Vincen Wu, Yulia Panina, Andres Mendez-Lucas, Catherine MacLachlan, Neill Patani, Catherine B Hubert, Helen Huang, Gina Greenidge, Oscar M Rueda, Adam J Taylor, Evdoxia Karali, Emine Kazanc, Amy R Spicer-Hadlington, Alex Dexter, Wei Lin, Daria Thompson, Mariana Silva Dos Santos, Enrica Calvani, Nathalie M Legrave, James K Ellis, Wendy Greenwood, Mary Green, Emma Nye, Emma Still, null null, Simon T Barry, Richard J A Goodwin, Alejandra Bruna, Carlos Caldas, James I MacRae, Luiz Pedro Sório de Carvalho, George Poulogiannis, Greg McMahon, Zoltán Takáts, Josephine Bunch, Mariia O Yuneva
Vitamin B 5 supports MYC oncogenic metabolism and tumor progression in breast cancer. Nature metabolism (2023)
Simon T Barry, Dmitry I Gabrilovich, Owen James Sansom, Andrew D Campbell, Jennifer P Morton
Therapeutic targeting of tumour myeloid cells. Nature reviews. Cancer (2023)
Lorna Hopcroft, Eleanor M Wigmore, Stuart Charles Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer 9 (1) (2023)
Dustin J Flanagan, Raheleh Amirkhah, David F Vincent, Nuray Gunduz, Pauline Gentaz, Patrizia Cammareri, Aoife J McCooey, Amy M B McCorry, Natalie C Fisher, Hayley L Belnoue-Davis, Rachel A Ridgway, Jeroen Lohuis, Joshua D G Leach, Rene Jackstadt, Kathryn Gilroy, Elisa Mariella, Colin Nixon, William Clark, Ann Hedley, Elke K Markert, Douglas Strathdee, Laurent Bartholin, Keara L Redmond, Emma M Kerr, Daniel B Longley, Fiona Ginty, Sanghee Cho, Helen G Coleman, Maurice B Loughrey, Alberto Bardelli, Timothy S Maughan, Andrew D Campbell, Mark Lawler, Simon J Leedham, Simon T Barry, Gareth J Inman, Jacco van Rheenen, Philip David Dunne, Owen James Sansom
Author Correction: Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nature communications 14 (1) (2023)
Xu Zhou, Jingyu An, Roma Kurilov, Benedikt Brors, Kai Hu, Teresa Peccerella, Stephanie Roessler, Katrin Pfütze, Angela Schulz, Stephan Wolf, Nicolas Hohmann, Dirk Theile, Max Sauter, Juergen Burhenne, Shigenori Ei, Ulrike Heger, Oliver Strobel, Simon T Barry, Christoph Springfeld, Christine Tjaden, Frank Bergmann, Markus Büchler, Thilo Hackert, Franco Fortunato, John P Neoptolemos, Peter Bailey
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Nature cancer (2023)
Daniela Brina, Adele Ponzoni, Martina Troiani, Bianca Calì, Emiliano Pasquini, Giuseppe Attanasio, Simone Mosole, Michela Mirenda, Mariantonietta D'Ambrosio, Manuel Colucci, Ilaria Guccini, Ajinkya Revandkar, Abdullah Alajati, Toma Tebaldi, Deborah Donzel, Fabio Lauria, Nahjme Parhizgari, Aurora Valdata, Martino Maddalena, Arianna Calcinotto, Marco Bolis, Andrea Rinaldi, Simon T Barry, Jan Hendrik Rüschoff, Marianna Sabbadin, Semini Sumanasuriya, Mateus Crespo, Adam Sharp, Wei Yuan, Mathew Grinu, Alexandra Boyle, Cynthia Miller, Lloyd C Trotman, Nicolas Delaleu, Matteo Fassan, Holger Moch, Gabriella Viero, Johann S de Bono, Andrea Alimonti
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells. Nature cancer (2023)
Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh C Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I Fisher, Eric T Gangl, Hilary J Lewis, Dawn Trueman, Neha Wali, Stuart Charles Williamson, Jennifer I Moss, Elodie Montaudon, Héloïse Derrien, Elisabetta Marangoni, Ricardo J Miragaia, Sladjana Gagrica, Pablo Morentin Gutierrez, Thomas Moss, Gareth A Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E Critchlow, James S Scott, Justin P O Lindemann, Simon T Barry, Teresa Klinowska, Christopher J Morrow, Larissa S Carnevalli
The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance. Cancer research (2023)
Johan Vande Voorde, Rory T Steven, Arafath K Najumudeen, Catriona A Ford, Alex Dexter, Ariadna Gonzalez-Fernandez, Chelsea J Nikula, Yuchen Xiang, Lauren Ford, Stefania Maneta Stavrakaki, Kathryn L Gilroy, Lucas B Zeiger, Kathryn Pennel, Phimmada Hatthakarnkul, Efstathios A Elia, Ammar Nasif, Teresa Murta, Eftychios Manoli, Sam Mason, Michael Gillespie, Tamsin R M Lannagan, Nikola Vlahov, Rachel A Ridgway, Colin Nixon, Alexander Raven, Megan Mills, Dimitris Athineos, Georgios Kanellos, Craig Nourse, David M Gay, Mark Hughes, Amy Burton, Bin Yan, Katherine Sellers, Vincen Wu, Kobe De Ridder, Engy Shokry, Alejandro Huerta Uribe, William Clark, Graeme Clark, Kristina Kirschner, Bernard Thienpont, Vivian Sze Wing Li, Oliver D K Maddocks, Simon T Barry, Richard J A Goodwin, James Macalister Kinross, Joanne Edwards, Mariia O Yuneva, David Sumpton, Zoltán Takáts, Andrew D Campbell, Josephine Bunch, Owen James Sansom
Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target. Nature metabolism (2023)
Simon T Barry, Dmitry I Gabrilovich, Owen James Sansom, Andrew D Campbell, Jennifer P Morton
Therapeutic targeting of tumour myeloid cells. Nature reviews. Cancer (2023)
Lorna Hopcroft, Eleanor M Wigmore, Stuart Charles Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffman, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer 9 (1) (2023)
Dustin J Flanagan, Raheleh Amirkhah, David F Vincent, Nuray Gunduz, Pauline Gentaz, Patrizia Cammareri, Aoife J McCooey, Amy M B McCorry, Natalie C Fisher, Hayley L Belnoue-Davis, Rachel A Ridgway, Jeroen Lohuis, Joshua D G Leach, Rene Jackstadt, Kathryn Gilroy, Elisa Mariella, Colin Nixon, William Clark, Ann Hedley, Elke K Markert, Douglas Strathdee, Laurent Bartholin, Keara L Redmond, Emma M Kerr, Daniel B Longley, Fiona Ginty, Sanghee Cho, Helen G Coleman, Maurice B Loughrey, Alberto Bardelli, Timothy S Maughan, Andrew D Campbell, Mark Lawler, Simon J Leedham, Simon T Barry, Gareth J Inman, Jacco van Rheenen, Philip David Dunne, Owen James Sansom
Author Correction: Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nature communications 14 (1) (2023)
Wendan Xu, Philipp Berning, Tabea Erdmann, Michael Grau, Nardjas Bettazová, Myroslav Zapukhlyak, Fabian Frontzek, Corinna Kosnopfel, Peter Lenz, Michael Grondine, Brandon Willis, James T Lynch, Pavel Klener, Stephan Hailfinger, Simon T Barry, Georg Lenz
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma. Leukemia (2022)
Dustin J Flanagan, Raheleh Amirkhah, David F Vincent, Nuray Gundaz, Pauline Gentaz, Patrizia Cammareri, Aoife J McCooey, Amy M B McCorry, Natalie C Fisher, Hayley L Belnoue-Davis, Rachel A Ridgway, Jeroen Lohuis, Joshua D G Leach, Rene Jackstadt, Kathryn Gilroy, Elisa Mariella, Colin Nixon, William Clark, Ann Hedley, Elke K Markert, Douglas Strathdee, Laurent Bartholin, Keara L Redmond, Emma M Kerr, Daniel B Longley, Fiona Ginty, Sanghee Cho, Helen G Coleman, Maurice B Loughrey, Alberto Bardelli, Timothy S Maughan, Andrew D Campbell, Mark Lawler, Simon J Leedham, Simon T Barry, Gareth J Inman, Jacco van Rheenen, Philip David Dunne, Owen James Sansom
Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nature communications 13 (1) (2022)
Shanade Dunn, Cath Eberlein, Jason Yu, Albert Gris-Oliver, Swee Hoe Ong, Urs Yelland, Natalie Cureton, Anna Staniszewska, Robert McEwen, Millie Fox, James Pilling, Philip Hopcroft, Elizabeth A Coker, Patricia Jaaks, Mathew J Garnett, Beverley Isherwood, Violeta Serra, Barry R Davies, Simon T Barry, James T Lynch, Kosuke Yusa
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene 41 (46) (2022)
Atish D Choudhury, Celestia S Higano, Johann S de Bono, Natalie Cook, Dana E Rathkopf, Kari B Wisinski, Juan Martin-Liberal, Mark Linch, Elisabeth I Heath, Richard D Baird, Javier García Corbacho, Miguel Quintela-Fandino, Simon T Barry, Elza C de Bruin, Steve Colebrook, George Hawkins, Teresa Klinowska, Brijesh Maroj, Ganesh Moorthy, Peter G S Mortimer, Michele Moschetta, Myria Nikolaou, Liz Sainsbury, Geoffrey I Shapiro, Lillian L Siu, Aaron Richard Hansen
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (11) (2022)
Larissa S Carnevalli, Molly Ann Taylor, Matthew King, Anna M L Coenen-Stass, Adina M Hughes, Sigourney Bell, Theresa A Proia, Yanjun Wang, Antonio Ramos-Montoya, Neha Wali, Danielle Carroll, Maneesh Singh, Michele Moschetta, Pablo Morentin Gutierrez, Cristina Gardelli, Susan E Critchlow, Teresa Klinowska, Stephen E Fawell, Simon T Barry
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition. Molecular cancer therapeutics 20 (6) (2021)
Owen Heath, Chiara Berlato, Eleni Maniati, Anissa Lakhani, Colin Pegrum, Panoraia Kotantaki, Samar Elorbany, Steffen Böhm, Simon T Barry, Alessandro Annibaldi, Desmond P Barton, Frances R Balkwill
Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer. Cancer immunology research 9 (6) (2021)
Miriam Marqués, Robin Tranchant, Blanca Risa-Ebrí, María L Suárez-Solís, Luis C Fernández, Enrique Carrillo de Santa Pau, Natalia Del Pozo, Jaime Martínez de Villarreal, Clément Meiller, Yves Allory, Yuna Blum, Christine Pirker, Balazs Hegedüs, Simon T Barry, Amancio Carnero, Walter Berger, Didier Jean, Francisco X Real
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. Cancer research 80 (4) (2020)
Theresa A Proia, Maneesh Singh, Richard Woessner, Larissa S Carnevalli, Gayathri Bommakanti, Lukasz Magiera, Srimathi Srinivasan, Shaun Grosskurth, Michael P Collins, Chris Womack, Matthew Griffin, Minwei Ye, Susan Cantin, Deanna L Russell, Mingchao Xie, Adina M Hughes, Nanhua Deng, Deanna A Mele, Stephen Fawell, Simon T Barry, Corinne Reimer, J Carl Barrett, Patricia McCoon
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (23) (2020)